Alnylam Pharmaceuticals Price To Earning vs. Return On Asset

ALNY Stock  USD 253.07  0.67  0.26%   
Based on Alnylam Pharmaceuticals' profitability indicators, Alnylam Pharmaceuticals' profitability may be sliding down. It has an above-average odds of reporting lower numbers next quarter. Profitability indicators assess Alnylam Pharmaceuticals' ability to earn profits and add value for shareholders. Operating Cash Flow Sales Ratio is likely to rise to 0.06 in 2024, whereas Price To Sales Ratio is likely to drop 12.42 in 2024. At this time, Alnylam Pharmaceuticals' Income Tax Expense is fairly stable compared to the past year. Interest Income is likely to rise to about 100.3 M in 2024, despite the fact that Accumulated Other Comprehensive Income is likely to grow to (22.2 M).
Current ValueLast YearChange From Last Year 10 Year Trend
Gross Profit Margin0.960.8302
Fairly Up
Pretty Stable
For Alnylam Pharmaceuticals profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Alnylam Pharmaceuticals to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Alnylam Pharmaceuticals utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Alnylam Pharmaceuticals's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Alnylam Pharmaceuticals over time as well as its relative position and ranking within its peers.
  

Alnylam Pharmaceuticals' Revenue Breakdown by Earning Segment

Check out Trending Equities.
For more information on how to buy Alnylam Stock please use our How to Invest in Alnylam Pharmaceuticals guide.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Alnylam Pharmaceuticals. If investors know Alnylam will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Alnylam Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.61)
Revenue Per Share
16.524
Quarterly Revenue Growth
(0.33)
Return On Assets
(0.03)
Return On Equity
(15.01)
The market value of Alnylam Pharmaceuticals is measured differently than its book value, which is the value of Alnylam that is recorded on the company's balance sheet. Investors also form their own opinion of Alnylam Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Alnylam Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Alnylam Pharmaceuticals' market value can be influenced by many factors that don't directly affect Alnylam Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Alnylam Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Alnylam Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Alnylam Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Alnylam Pharmaceuticals Return On Asset vs. Price To Earning Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Alnylam Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Alnylam Pharmaceuticals value to that of its competitors to determine the firm's financial worth.
Alnylam Pharmaceuticals is rated below average in price to earning category among its peers. It is rated below average in return on asset category among its peers . Return On Assets is likely to drop to -0.12 in 2024. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Alnylam Pharmaceuticals' earnings, one of the primary drivers of an investment's value.

Alnylam Pharmaceuticals' Earnings Breakdown by Geography

Alnylam Return On Asset vs. Price To Earning

Price to Earnings ratio is typically used for current valuation of a company and is one of the most popular ratios that investors monitor daily. Holding a low PE stock is less risky because when a company's profitability falls, it is likely that earnings will also go down as well. In other words, if you start from a lower position, your downside risk is limited. There are also some investors who believe that low Price to Earnings ratio reflects the low pricing because a given company is in trouble. On the other hand, a higher PE ratio means that investors are paying more for each unit of profit.

Alnylam Pharmaceuticals

P/E

 = 

Market Value Per Share

Earnings Per Share

 = 
(22.92) X
Generally speaking, the Price to Earnings ratio gives investors an idea of what the market is willing to pay for the company's current earnings.
Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.

Alnylam Pharmaceuticals

Return On Asset

 = 

Net Income

Total Assets

 = 
-0.0292
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.

Alnylam Return On Asset Comparison

Alnylam Pharmaceuticals is currently under evaluation in return on asset category among its peers.

Alnylam Pharmaceuticals Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Alnylam Pharmaceuticals, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Alnylam Pharmaceuticals will eventually generate negative long term returns. The profitability progress is the general direction of Alnylam Pharmaceuticals' change in net profit over the period of time. It can combine multiple indicators of Alnylam Pharmaceuticals, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last ReportedProjected for Next Year
Accumulated Other Comprehensive Income-23.4 M-22.2 M
Operating Income-282.2 M-296.3 M
Net Loss-440.2 M-462.3 M
Income Tax Expense6.7 M7.1 M
Income Before Tax-433.5 M-455.2 M
Total Other Income Expense Net-151.3 M-143.8 M
Net Loss-440.2 M-462.3 M
Non Operating Income Net Other-167.4 M-159 M
Net Loss-1 B-967.1 M
Interest Income95.6 M100.3 M
Net Interest Income-25.7 M-26.9 M
Change To Netincome353.9 M371.6 M
Net Loss(3.52)(3.70)
Income Quality(0.24)(0.22)
Net Income Per E B T 1.02  0.78 

Alnylam Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Alnylam Pharmaceuticals. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Alnylam Pharmaceuticals position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Alnylam Pharmaceuticals' important profitability drivers and their relationship over time.

Use Alnylam Pharmaceuticals in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Alnylam Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Alnylam Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Alnylam Pharmaceuticals Pair Trading

Alnylam Pharmaceuticals Pair Trading Analysis

The ability to find closely correlated positions to Alnylam Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Alnylam Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Alnylam Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Alnylam Pharmaceuticals to buy it.
The correlation of Alnylam Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Alnylam Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Alnylam Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Alnylam Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Alnylam Pharmaceuticals position

In addition to having Alnylam Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Measuring and Control Equipment Thematic Idea Now

Measuring and Control Equipment
Measuring and Control Equipment Theme
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Measuring and Control Equipment theme has 61 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Measuring and Control Equipment Theme or any other thematic opportunities.
View All  Next Launch

Additional Tools for Alnylam Stock Analysis

When running Alnylam Pharmaceuticals' price analysis, check to measure Alnylam Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Alnylam Pharmaceuticals is operating at the current time. Most of Alnylam Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Alnylam Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Alnylam Pharmaceuticals' price. Additionally, you may evaluate how the addition of Alnylam Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.